PND3 Risk-Benefit Analysis of Therapy in Multiple Sclerosis

Value in Health - United Kingdom
doi 10.1016/j.jval.2011.08.469
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Symptomatic Therapy in Multiple Sclerosis

Therapeutic Advances in Neurological Disorders
NeurologyPharmacology
2011English

Cyclophosphamide Therapy in Pediatric Multiple Sclerosis

Neurology
Neurology
2009English

Cytoflavin in the Complex Therapy of Multiple Sclerosis

Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova
PsychiatryMental HealthNeurology
2018English

Laquinimod Therapy in Multiple Sclerosis: A Comprehensive Review

Neurology and Therapy
Neurology
2014English

Stem Cell Therapy in Patients With Multiple Sclerosis

Multiple Sclerosis
Neurology
2006English

Menarche Increases Relapse Risk in Pediatric Multiple Sclerosis

Multiple Sclerosis
Neurology
2015English

Multiple Sclerosis Risk After Optic Neuritis

Archives of Neurology
2008English

Multiple Sclerosis Disease-Modifying Therapy and Pregnancy

Multiple Sclerosis
Neurology
2016English

Vitamin D Role in Multiple Sclerosis Etiology and Therapy

Medicinski Casopis
Medicine
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2025 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy